Percutaneous Sclerotherapy With Bleomycin Effective, Tolerable

This article originally appeared here.
Share this content:
Percutaneous Sclerotherapy With Bleomycin Effective, Tolerable
Percutaneous Sclerotherapy With Bleomycin Effective, Tolerable

FRIDAY, Sept. 22, 2017 (HealthDay News) -- Percutaneous bleomycin injections are effective and tolerable for the treatment of vascular malformations, according to a study published online Sept. 4 in the International Journal of Dermatology.

Hyun-Joo Lee, M.D., from the Pusan National University in Busan, South Korea, and colleagues evaluated the therapeutic efficacy and safety of percutaneous sclerotherapy using bleomycin for the treatment of vascular malformations in 30 patients. A mean of 3.2 treatment sessions were conducted over an average of three months.

The researchers found that significant improvement was observed in 90.0 percent of all lesions. There was significant improvement in all lesions of capillary malformation with nodular change and lymphatic malformation, as well as in 82.4 percent of lesions of venous malformation. Side effects, including pain and headache (rated as tolerable), occurred within 24 hours in seven patients (23.3 percent).

"Percutaneous sclerotherapy using bleomycin is effective and tolerable in the treatment of vascular malformation through a percutaneous approach," the authors write. "Therefore, it could be applied usefully for vascular malformations by dermatologists."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »